In:
Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 145, No. Suppl_1 ( 2022-03)
Abstract:
Introduction: Low-density lipoprotein cholesterol (LDL-C) reduction is a cornerstone to atherosclerotic disease (ASCSVD) prevention. Iatrogenic LDL-C elevation may counteract measures to address ASCVD risk by LDL-C lowering. Methods: Participant data from the National Health and Nutrition Examination Survey (NHANES) between 2013-2018 was pooled to determine the use of medication that raised LDL-C as an adverse effect as determined by literature review. Logistic regression was used to determine the association between the use of LDL-C raising medication and ASCVD with adjustment for demographic, socioeconomic, and health-related variables. Results: Among NHANES participants with medication data availability (weighted n = 238,995,360), 4.9% were taking LDL-C raising medication. Among adults with ACSVD, 5.5% were taking LDL-C raising medication, compared to 4.7% of participants without ASCVD. LDL-C raising medication were more common among participants with an annual income 〈 $20,000, diagnosed with hypertension, taking an antihypertensive medication, greater BMI, and greater medication count. The unadjusted odds-ratio (OR) of the use of LDL-C raising medication with ASCVD was 1.18 (95% CI 0.97,1.44). Following adjustment for demographic, socioeconomic, and health-related variables the OR was further attenuated (OR 1.08 95% CI 0.82, 1.43). Discussion: In this analysis of NHANES, LDL-C raising medication was not associated with presence of ASCVD. However, the use of LDL-C raising medication was prevalent among nearly 5% of U.S. adults and greater monitoring of adverse medication effects may represent an avenue to improve LDL-C reduction
Type of Medium:
Online Resource
ISSN:
0009-7322
,
1524-4539
DOI:
10.1161/circ.145.suppl_1.EP31
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2022
detail.hit.zdb_id:
1466401-X
